Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Auro Laboratories Ltd

Your Vote -

Buy

75.00%

Hold

0.00%

Sell

25.00%

75.00%

4 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Auro Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Auro Labs Q3 net profit down 98.17% at Rs 0.05 cr

    14 Feb 2025, 6:10PM The company reported standalone net profit of Rs 0.05 crore for the quarter ended December 31, 2024 as compared to Rs 2.73 crore in the same period la
  • Auro Labs - Appointment of Company Secretary and Compliance Officer

    14 Feb 2025, 5:56PM Attached herewith is the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
  • Auro Labs - Integrated Filing (Financial)

    14 Feb 2025, 5:52PM Attached herewith Integrated Financials for the Quarter ended December 31, 2024.
  • Auro Labs - Unaudited Financial Results For The Quarter Ended December 31, 2024.

    14 Feb 2025, 5:45PM Attached herewith Unaudited Financial Results of the company for the Quarter ended December 31, 2024.
  • Auro Labs - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD ON FEBRUARY 14, 2025.

    14 Feb 2025, 5:34PM Attached herewith Outcome of the Board Meeting.
  • Auro Labs - Board Meeting Intimation for Approval Of Unaudited Financial Results For Quarter Ended December 31, 2024.

    7 Feb 2025, 4:35PM AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 ,inter alia, to consider a
  • Auro Labs has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    21 Jan 2025, 6:20PM As of December 2024, 52.15% is owned by Indian Promoters and 47.85% by Public. <p align=justify> Top five Promoters holding highest number of shares o
  • Auro Labs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    15 Jan 2025, 1:42PM Auro Laboratories Limited has submitted the certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 issued by the R
  • Auro Labs - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

    16 Dec 2024, 11:17PM Auro Laboratories Limited wishes to inform you that Ms. Shaan Jain has resigned from the post of Chief Financial Officer (KMP) of the Company with eff

Key fundamentals

Evaluate the intrinsic value of Auro Laboratories Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 68.2024 40.3588 32.3704 30.6213 23.3073
Liabilities 68.2024 40.3588 32.3704 30.6213 23.3073
Equity 6.2325 6.2325 6.2325 6.2325 6.2325
Gross Profit 10.6698 4.3927 4.625 11.2415 6.1588
Net Profit 7.7921 2.442 2.8446 7.1795 4.0544
Cash From Operating Activities 18.8071 3.2812 -6.5904 5.7998 9.1888
NPM(%) 14.52 4.61 5.59 13.23 9.25
Revenue 53.6352 52.8942 50.8658 54.2518 43.7906
Expenses 42.9654 48.5015 46.2407 43.0102 37.6317
ROE(%) 18.57 5.82 6.77 17.11 9.66

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Auro Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 809.25 -0.64 11.41 128.87 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 58.19 1.50 237.75 469.58 14.01 0.88
Bharat Immunological and Biologicals Corporation Ltd 21.32 -1.30 0.00 975.00 -39.50 0.00
Astec Lifesciences Ltd 654.90 -5.39 0.00 442.77 -239.30 0.00

Company Info

Auro Laboratories Limited was incorporated as a Private Limited Company on 26th May 1989 with the Registrar of Companies, Maharashtra at Bombay. Later on the Company has been converted into a Limited Company on 13th January 1994 vide resolution dated 21st September, 1993. The Company is promoted by Shri Sharat Deorah and Shri Satish Deorah. After incorporation the Company took all effective steps to set up the manufacturing facilities at Tarapur, Maharashtra by acquiring on lease a suitable plot of land at MIDC Industrial Area and with the aid of State Industrial & Investment Corporation of Maharashtra (SICOM) & Maharashtra State Finance Corporation (MSFC). The Company was successful in implementing the project and started its commercial production on 14th July, 1992. The Company is engaged in the manufacturing and trading of TRIMETHOPRIM (lP/BP/USP), a bulk drug. TMP is an antibacterial drug and is used in combination with SULPHAMETHOXAZOLE (SMX). The plant of the Company is located at K-56, MIDC Industrial Area, Tarapur, Boisar, Dist. Thane, Maharashtra with production capacity of 60 TPA of TMP. The Company is managed by the Board of Directors which includes well experienced businessmen and professionals, Shri Sharat Deorah, the Promoter-Director of the Company is the Managing Director. He possesses experience of various business activities for more than 2 decades. This includes road transport, tea warehousing and manufacturing and exports of bulk drugs. Shri Satish Deorah is the younger brother of Shri Sharat Deorah. He too holds experience spanning over more than 17 years in the business activities of transport, tea warehousing and manufacturing and exports of bulk drugs. Shri Sharat Deorah is stationed at Bombay whereas Shri Satish Deorah at Calcutta. The Company is now planning to undertake the project for expansion of production capacity of TMP from the existing 60 TPA to 200 TPA. Besides, the Company is also planning for backward integration by commencing the production of 3-4-5 TRIMETHOXYBENZALDEHYDE (TMBA), which is the basic raw material for the production of TMP. The Company has already received the Letter of Intent for the production of 3-4-5 TMBA vide the Letter of Secretariat for Industrial Approvals, Dept. of Industrial Development, Ministry of Industry, Govt. of India bearing No. LI:34 (1994) dated 11th January 1994. The Company has further made an application to the Central Government for the amendment of the licence with respect to increase in the production capacity of 3-4-5 TMBA. The plant will have a capcity of 175 TPA of the production of 3-4-5 TMBA from 275 TPA of Gallic Acid, which will be consumed entirely by the Company. Out of the total production, 50% of TMP would be exported During the year 1993-94, the Company made export worth Rs. 45 lacs and is planning to achieve an export target of Rs. 1.50 crores during the current year. So far, the Company has been involved in the manufacturing and trading of TMP, a bulk drug. One of the group companies, Auro Impex Private Limited has a very successful track record in the exports of bulk drug items. With a view to reap benefits of the backward integration, the Company is now planning to commence manufacturing of 3-4-5 TMBA. MAIN OBJECTS The main objects of the Company as set out in its Memorandum of Association are as follows : 1. To manufacture, process, derive, buy, sell, import, export, or otherwise deal in pharmaceutical, medicinal, diagnostic, antibiotic, antiseptic, disinfectants, optical, biological, immunological, therapeutic and healthcare products, preparations, compounds and intermediates. 2. To manufacture, process, derive, buy, sell, import, export or otherwise deal in cosmetics whether herbal or otherwise hair, skin, nail or other beauty preparations, perfumes, aromatic chemicals, toiletories, deodorants, hair dyes and hygienic house hold consumer products. 2006 -Received Certificate of Suitability (COS) of Metformin Hydrochloride from EDQM.

Auro Laboratories Limited was incorporated as a Private Limited Company on 26th May 1989 with the Registrar of Companies, Maharashtra at Bombay. Later on the Company has been converted into a Limited Company on 13th January 1994 vide resolution dated 21st September, 1993. The Company is promoted by Shri Sharat Deorah and Shri Satish Deorah. After incorporation the Company took all effective steps to set up the manufacturing facilities at Tarapur, Maharashtra by acquiring on lease a suitable plot of land at MIDC Industrial Area and with the aid of State Industrial & Investment Corporation of Maharashtra (SICOM) & Maharashtra State Finance Corporation (MSFC). The Company was successful in implementing the project and started its commercial production on 14th July, 1992. The Company is engaged in the manufacturing and trading of TRIMETHOPRIM (lP/BP/USP), a bulk drug. TMP is an antibacterial drug and is used in combination with SULPHAMETHOXAZOLE (SMX). The plant of the Company is located at K-56, MIDC Industrial Area, Tarapur, Boisar, Dist. Thane, Maharashtra with production capacity of 60 TPA of TMP. The Company is managed by the Board of Directors which includes well experienced businessmen and professionals, Shri Sharat Deorah, the Promoter-Director of the Company is the Managing Director. He possesses experience of various business activities for more than 2 decades. This includes road transport, tea warehousing and manufacturing and exports of bulk drugs. Shri Satish Deorah is the younger brother of Shri Sharat Deorah. He too holds experience spanning over more than 17 years in the business activities of transport, tea warehousing and manufacturing and exports of bulk drugs. Shri Sharat Deorah is stationed at Bombay whereas Shri Satish Deorah at Calcutta. The Company is now planning to undertake the project for expansion of production capacity of TMP from the existing 60 TPA to 200 TPA. Besides, the Company is also planning for backward integration by commencing the production of 3-4-5 TRIMETHOXYBENZALDEHYDE (TMBA), which is the basic raw material for the production of TMP. The Company has already received the Letter of Intent for the production of 3-4-5 TMBA vide the Letter of Secretariat for Industrial Approvals, Dept. of Industrial Development, Ministry of Industry, Govt. of India bearing No. LI:34 (1994) dated 11th January 1994. The Company has further made an application to the Central Government for the amendment of the licence with respect to increase in the production capacity of 3-4-5 TMBA. The plant will have a capcity of 175 TPA of the production of 3-4-5 TMBA from 275 TPA of Gallic Acid, which will be consumed entirely by the Company. Out of the total production, 50% of TMP would be exported During the year 1993-94, the Company made export worth Rs. 45 lacs and is planning to achieve an export target of Rs. 1.50 crores during the current year. So far, the Company has been involved in the manufacturing and trading of TMP, a bulk drug. One of the group companies, Auro Impex Private Limited has a very successful track record in the exports of bulk drug items. With a view to reap benefits of the backward integration, the Company is now planning to commence manufacturing of 3-4-5 TMBA. MAIN OBJECTS The main objects of the Company as set out in its Memorandum of Association are as follows : 1. To manufacture, process, derive, buy, sell, import, export, or otherwise deal in pharmaceutical, medicinal, diagnostic, antibiotic, antiseptic, disinfectants, optical, biological, immunological, therapeutic and healthcare products, preparations, compounds and intermediates. 2. To manufacture, process, derive, buy, sell, import, export or otherwise deal in cosmetics whether herbal or otherwise hair, skin, nail or other beauty preparations, perfumes, aromatic chemicals, toiletories, deodorants, hair dyes and hygienic house hold consumer products. 2006 -Received Certificate of Suitability (COS) of Metformin Hydrochloride from EDQM.

Read More

Parent Organisation

Auro Laboratories Ltd.

Founded

26/05/1989

Managing Director

Mr.Sharat Deorah

NSE Symbol

FAQ

The current price of Auro Laboratories Ltd is

The 52-week high for Auro Laboratories Ltd is

The market capitalization of Auro Laboratories Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Auro Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Auro Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Auro Laboratories Ltd shares.

The CEO of Auro Laboratories Ltd is Mr.Sharat Deorah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT